Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Pseudomonas Infection Clinical Trial

Official title:
A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder

Status Completed

Clinical Trial Summary

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00910351
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 1
Start date	July 2009
Completion date	October 2010

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00529282` - A Study of Ceftobiprole in Patients With Fever and Neutropenia.	Phase 3
Completed	`NCT00027183` - Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
Completed	`NCT02178254` - Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects	Phase 1